ambroxol oral / Generic mfg. - LARVOL DELTA

Mechanical ventilation strategies and lung protection during cardiopulmonary bypass: A scoping review. (PubMed, Perfusion) - "When combined with protective measures (low tidal volume [LTV], moderate positive end-expiratory pressure [PEEP], and recruitment maneuvers), they show clinical efficacy in lung protection. Pharmacologic agents like ambroxol, neutrophil elastase inhibitors, and sivelestat further enhance protection, underscoring the promise of combined mechanical-pharmacological strategies against CPB-induced lung injury.ConclusionsA comprehensive approach integrating individualized ventilation management and pharmacological intervention is key to reducing CPB-induced lung injury, enhancing postoperative respiratory function, and improving patient outcomes."

Journal • Review • Cardiovascular • Inflammation • Respiratory Diseases • ELANE

Exploring the long-term use of ambroxol in Gaucher disease type 2: insights from two pediatric cases. (PubMed, Front Neurol) - "Neurocognitive and motor function assessments at 40 months of age indicated a moderate to severe developmental delay, yet continuous developmental progress. These interim findings contribute to the mounting evidence supporting ABX as a variant-dependent treatment for GD2 patients."

Journal • Developmental Disorders • Gaucher Disease • Genetic Disorders • Lysosomal Storage Diseases • Metabolic Disorders • Pediatrics • Rare Diseases

The protective effect of ambroxol against cyclophosphamide-induced acute kidney injury involves Nrf2/HO-1 signaling upregulation and suppression of oxidative and inflammatory damage. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In conclusion, these findings suggest that ABX confers nephroprotection against CP-induced injury primarily through its antioxidant, anti-inflammatory, and anti-apoptotic actions, partly via modulation of the Keap-1/Nrf2/HO-1 pathway. These findings support potential repurposing of ABX as a nephroprotective adjuvant during CP chemotherapy and warrant further clinical investigation."

Journal • Acute Kidney Injury • Inflammation • Nephrology • Renal Disease • CASP3 • CAT • IL1B • KEAP1 • KIM1 • TNFA

Comparative efficacy of doxophylline-ambroxol combination versus aminophylline in the management of acute exacerbations of COPD: A retrospective case-control study. (PubMed, Pak J Pharm Sci) - "Doxophylline-ambroxol combination therapy is more effective than aminophylline in improving pulmonary function and reducing inflammation in AECOPD, with equivalent safety."

Clinical • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Clinical Application of BAL Combined with Microscopic Spraying Inhalation of Sputum Mucus Lysate in the Treatment of Non asthmatic and Refractory Pneumonia in Children (ChiCTR) - P=N/A | N=108 | Completed | Sponsor: Guangzhou Panyu District Central Hospital; Guangzhou Panyu District Central Hospital

New trial • Asthma • Infectious Disease • Pneumonia • Respiratory Diseases

Drug-Induced Liver Injury with Eosinophilia: A Case-Control Study Using Electronic Medical Records. (PubMed, Biol Pharm Bull) - "Sulbactam/cefoperazone showed the strongest association with DILI-Eos (adjusted odds ratio (OR) 14.51; 95% confidence interval (CI) 10.09-20.85), followed by meropenem (OR 5.68; 95% CI 4.10-7.82) and tazobactam/piperacillin (OR 3.55; 95% CI 2.63-4.75). Several commonly used drugs, such as mosapride, lansoprazole, furosemide, and ambroxol, were also significantly associated with increased risk...Notably, substantial variability in risk was observed even within the same drug classes, such as β-lactam antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), underscoring the importance of drug-specific evaluation. Further studies are needed to clarify the causality and mechanisms underlying eosinophilic responses in DILI."

Journal • Eosinophilia • Hepatology • Immunology • Liver Failure

INVESTIGATING NOVEL BIOMARKERS IN PRE-CLINICAL MODELS OF PARKINSON'S DISEASE (ADPD 2026) - " Primary rat dopaminergic neurons were injured with α-syn PFF and conduritol B epoxide (CBE; GBA inhibitor; 20 µM) +/- Ambroxol (500 nM)... In conclusion, we have shown that our in-vitro and in-vivo models of PD are useful, translatable tools to detect biochemical changes that can serve as biomarkers of disease progression. These results support the development of novel biomarkers for PD to improve disease detection and early intervention."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

UPDATE ON THE GRONINGEN EARLY-PD AMBROXOL TREATMENT (GREAT) TRIAL: A RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, SINGLE CENTER TRIAL WITH AMBROXOL IN PARKINSON PATIENTS WITH A GBA MUTATION (ADPD 2026) - "1. Ambroxol up to 1800 mg per day is well-tolerated 2. The currently included GBA mutations are mainly risk variants"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • GBA • GBA1

AMBROXOL DISPLACES ALPHA-SYNUCLEIN FROM THE MEMBRANE AND INHIBITS THE FORMATION OF EARLY PROTEIN-LIPID COAGGREGATES (ADPD 2026) - "These results suggest that Ambroxol may have beneficial effects on other synucleinopathies, such as multiple system atrophy and dementia with Lewy Bodies, that are also characterised by the aggregation of αS into amyloid fibrils."

Alzheimer's Disease • CNS Disorders • Dementia • Lewy Body Disease • Metabolic Disorders • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • GBA

THE EFFECTS OF 78-WEEK TREATMENT WITH AMBROXOL ON COGNITIVE, MOTOR, AND NEUROPSYCHIATRIC SYMPTOMS IN PARKINSON'S DISEASE DEMENTIA (ADPD 2026) - P2 | "Ambroxol had an overall positive effect on neuropsychiatric symptoms over 78 weeks, whereas only GBA1 mutation carriers seemed to show cognitive benefit. Safety and pharmacology in the OLE were similar to the double-blind phase."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Movement Disorders • Parkinson's Disease • Psychiatry • GBA • GBA1

First use of nitazoxanide in Kelleni's protocol for managing severe bronchiolitis in a 9-month-old infant: A case report and review of literature. (PubMed, World J Clin Cases) - "To the best of my knowledge, this report presents, for the first time globally, a potential of nitazoxanide within Kelleni's protocol to early manage infants younger than one year suffering from severe lower respiratory tract viral infection at home. Selective antitussive treatment, using agents such as low dose benproperine, was employed to mitigate troublesome cough and improve patient comfort without compromising respiratory function. Additionally, alpha amylase was used to facilitate pulmonary secretion clearance. The protocol aims to reduce morbidity and mortality from viral lower respiratory tract infections in this vulnerable population."

Journal • Cough • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Can We Develop Glioma Subtype-Specific Precision Medicines? An Integrative Machine Learning Pipeline for Biomarker Discovery and Drug Repurposing for Glioblastoma and Low-Grade Glioma. (PubMed, OMICS) - "Repurposed drug candidates were then predicted via signature-based prioritization and evaluated using molecular docking simulations, revealing six promising compounds for GBM (vandetanib, capecitabine, melatonin, agomelatine, ramelteon, and tasimelteon) and one for LGG (ambroxol). This study demonstrates the utility of combining class-balancing, feature selection, and drug repurposing pipelines to uncover clinically relevant glioma biomarkers and therapeutic candidates, thus providing a computational foundation for future experimental and translational validation in these brain cancers and neuro-oncology."

Biomarker • Journal • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • ANK3

High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3) (clinicaltrials.gov) - P=N/A | N=12 | Active, not recruiting | Sponsor: Agyany Pharma LTD

New trial • Gaucher Disease • Genetic Disorders • Metabolic Disorders • Pediatrics • Type 1 Gaucher Disease

Long-term oral glucocerebrosidase activator reduces soluble α-synuclein oligomer accumulation in Parkinsonian LRRK2 mutant mouse brain. (PubMed, NPJ Parkinsons Dis) - "Here, we showed that long-term treatment of ambroxol (ABX), a brain-penetrant GCase activator, reduced α-syn oligomer accumulation in aged mutant LRRK2R1441G mouse striatum...This regimen significantly reduced α-syn oligomer level in mutant striatum to a comparable physiological level in age-matched WT without altering total α-syn and Ser129-phosphorylation levels. This is the first study demonstrating reduced α-syn oligomer accumulation by chronic treatment of GCase activator in aged mouse brains vulnerable to PD, suggesting early intervention to alter progression of synucleinopathies as a key determinant of clinical outcomes of PD."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • GBA • LRRK2

Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1-/-SNCAA53T double mutant mouse model of Parkinson's disease. (PubMed, Acta Pharmacol Sin) - "In addition, its lysosomal accumulation may further disrupt sphingolipid metabolism and impair mitochondrial compensatory mechanisms. Ambroxol-induced lysosomal exocytosis may transiently relieve αSyn burden, but further interventions would be required to ensure αSyn clearance from the brain."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Metabolic Disorders • Movement Disorders • Parkinson's Disease • GBA • GBA1

The use of genistein and ambroxol may be an effective approach in correcting cellular dysfunctions of mucopolysaccharidosis-plus syndrome. (PubMed, Mamm Genome) - "Using a line of MPSPS patient-derived fibroblasts, we demonstrated that treatment with genistein and ambroxol resulted in elevation of the mutant VPS33A protein level, as well as in improvement or correction of various previously reported cellular defects, including GAG levels, endosomal markers, and cytoskeleton elements. In the light of these results, and since both genistein and ambroxol were previously demonstrated to be safe when used in relatively high amounts, we suggest that the use of these compounds, and especially their combination, might be considered as a potential therapeutic approach in MPSPS, which is currently an incurable disease."

Journal • Metabolic Disorders • Targeted Protein Degradation

Ambroxol displaces α-synuclein from the membrane and inhibits the formation of early protein-lipid coaggregates. (PubMed, Chem Sci) - "We find that Ambroxol not only displaces α-synuclein from negatively charged membranes but also prevents the formation of early α-synuclein-lipid coaggregates during primary nucleation. These results suggest that Ambroxol may have beneficial effects on other synucleinopathies, such as multiple system atrophy and dementia with Lewy Bodies, that are also characterised by the aggregation of α-synuclein into amyloid fibrils."

Journal • CNS Disorders • Dementia • Lewy Body Disease • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • GBA

Ambroxol's Role in PTZ-Induced Anxiety-Like Conditions in Mice: Targeting Neuroinflammation and Oxidative Stress via In Vivo and In Silico Approaches. (PubMed, Mol Neurobiol) - "Ambroxol exhibited anxiolytic efficacy comparable to diazepam, with no apparent sedative effects observed behaviorally, although direct assessment of sedation (e.g., rotarod test) was not performed. Ambroxol demonstrated promising multi-target neuroprotective potential by concurrently attenuating oxidative and inflammatory cascades, supporting its further exploration as a safe, repurposed therapeutic candidate for anxiety disorders."

Journal • Preclinical • Anesthesia • CNS Disorders • Epilepsy • Inflammation • Mental Retardation • Mood Disorders • Psychiatry • IL1B • TNFA

Analysis of Solubility, pH, Antimicrobial Action and Cytotoxicity of Calcium Hydroxide Paste Associated With Ambroxol Hydrochloride. (PubMed, Aust Endod J) - "The association did not alter CH's cytotoxicity. Further research is needed for optimal ambroxol concentration."

Journal

Ambroxol: mechanisms of action and efficacy for inhaled therapy in the treatment of respiratory diseases. (PubMed, Recenti Prog Med) - "Moreover, ambroxol stimulates the synthesis of pulmonary surfactant, which, in addition to increasing lung compliance, preventing end-expiratory atelectasis, and facilitating the recruitment of collapsed airways, has anti-inflammatory, anti-infective, and immunoregulatory properties. Ambroxol inhalation represents an efficient way to reduce sputum viscosity, increase expectoration without increasing adverse events."

Journal • Pulmonary Disease • Respiratory Diseases

Exploring Novel Therapeutic Avenues: Drug Repurposing for Neurodegenerative Movement Disorders. (PubMed, Curr Drug Res Rev) - "Several studies on the potential of pre-existing drugs such as isradipine, tetracycline, ambroxol, metformin, deferiprone, simvastatin, etc., which have been repurposed for neurodegenerative movement disorders, including Parkinson's disease, Huntington's disease, Alzheimer's disease, Multiple Sclerosis, etc. have been discussed. Further, the current scenario and future prospective of drug repurposing have also been touched upon."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Huntington's Disease • Movement Disorders • Multiple Sclerosis • Parkinson's Disease

Perinatal-onset neuronopathic Gaucher disease is refractory to high-dose ambroxol: A case report and literature review. (PubMed, Neonatology) - "Ambroxol therapy may be insufficient to improve the prognosis of patients with PnGD, underscoring the limitations of early intervention in newborn-screened patients with GD. Therefore, pre-emptive therapeutic strategies are required to rescue and cure neonates with PnGD."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Epilepsy • Gaucher Disease • Genetic Disorders • Heart Failure • Hematological Disorders • Hepatology • Liver Failure • Metabolic Disorders

The development of ambroxol in als/mnd (ALS-MND 2025) - P2, P3 | "The role of patient associations could be critical depending on the business model applied, and any development spin-out configuration. These issues are typical of development of generic drugs for rare diseases and merit discussion."

Alzheimer's Disease • CNS Disorders • Dementia • Gaucher Disease • Genetic Disorders • Lewy Body Disease • Metabolic Disorders • Movement Disorders • Parkinson's Disease • Rare Diseases • Type 1 Gaucher Disease

Does Amyotrophic Lateral Sclerosis (ALS) Have Metabolic Causes from Human Evolution? (PubMed, Cells) - "A GBA2 inhibitor, ambroxol, is currently in phase II for ALS...Lipid/lactate metabolism changed to support these evolutionary changes and lactate is a major body/brain fuel, but compromised in ALS patients and a marker of disease progression. Recent progress in sports science involving lactate metabolism and human performance may also be relevant to ALS therapies, and incidence."

Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Infectious Disease

Ambroxol as adjunctive therapy for neurologic symptoms in Gaucher disease type 3: Case report. (SSIEM 2023) - No abstract available

Case report • Clinical • Gaucher Disease • Genetic Disorders • Metabolic Disorders